Other substances

ABBV-744

BRD inhibitor

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
2
 AI-suggested references
0
 Clinical trials

General information

ABBV-744 is a a BDII-selective BET bromodomain inhibitor that is being investigated to treat acute myeloid leukemia and metastic castration-resistant prostate cancer.

Regarding SARS-CoV-2, our AIM tool found the data that ABBV-744 could help against SARS-CoV-2 by modulating its interactors.

ABBV-744 on ABBVIE
ABBV-744 on PubChem

Synonyms

UNII-9MX546E2SF

 

Structure image - ABBV-744

C28H30FN3O4

Supporting references

Link Tested on Impact factor Notes Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Small molecule 		in silico 42.78 Apr/30/2020

AI-suggested references

Link Publication date
BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.
Jan/13/2022
ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
Jan/08/2021
Export (.csv)